Drug repositioning with adaptive graph convolutional networks.

Researchers

Journal

Modalities

Models

Abstract

Drug repositioning is an effective strategy to identify new indications for existing drugs, providing the quickest possible transition from bench to bedside. With the rapid development of deep learning, graph convolutional networks (GCNs) have been widely adopted for drug repositioning tasks. However, prior GCNs based methods exist limitations in deeply integrating node features and topological structures, which may hinder the capability of GCNs.In this study, we propose an adaptive graph convolutional networks approach, termed AdaDR, for drug repositioning by deeply integrating node features and topological structures. Distinct from conventional graph convolution networks, AdaDR models interactive information between them with adaptive graph convolution operation, which enhances the expression of model. Concretely, AdaDR simultaneously extracts embeddings from node features and topological structures and then uses the attention mechanism to learn adaptive importance weights of the embeddings. Experimental results show that AdaDR achieves better performance than multiple baselines for drug repositioning. Moreover, in the case study, exploratory analyses are offered for finding novel drug-disease associations.The implementation of AdaDR and the preprocessed data is available at: https://github.com/xinliangSun/AdaDR.Supplementary data are available at Bioinformatics online.© The Author(s) 2023. Published by Oxford University Press.